Cambrex Corp., a manufacturer of small molecule innovator and generic APIs, has expanded large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden and has introduced additional continuous flow manufacturing for the production of high purity intermediates.
 
The expansion includes the installation of new multi-purpose reactors ranging from 4m³ to 12m³ and upgrading of the control room within an existing plant on site. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which 3Q17.
 
Cambrex has also introduced a dedicated continuous flow production unit, capable of producing multiple metric tons of high purity intermediates per year.
 
“The additional capacity at the site, within our current infrastructure, will enable us to service our existing and future customers more efficiently,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. He added, “The continuous flow unit builds on our long experience with continuous flow and high energy chemistry and allows for greater production efficiency and flexibility.”